Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache

Unknown 21 enrolled Danish Headache Center

RandomizedCrossoverQuadruple-blindBasic science

Summary

To investigate whether cilostazol (phosphodiesterase 3 inhibitor) induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).

Timeline

Start: 2022-10-25
Primary completion: 2023-12-31
Completion: 2023-12-31

Outcome

Met primary endpoint

paper During the 12-hour observation window, 14 (67%) of 21 participants developed migraine-like headache post-cilostazol, in contrast to three (14%) participants after placebo (P =.003). PMID 38627631 ↗

Publications

Al-Khazali HM, Christensen RH, Chaudhry BA, Melchior AG, Ashina M, Burstein R, Ashina H. Effects of PDE-3 inhibition in persistent post-traumatic headache: evidence of cAMP-dependent signaling. J Headache Pain. 2024 Apr 17;25(1):56. doi: 10.1186/s10194-024-01762-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cilostazol	Small molecule	200 mg	Oral

Indications

No indication recorded.